Fabre-Kramer Pharmaceuticals, Inc. (“FKP” or the “Company”), was formed to identify, develop and commercialize psychotropic drugs with significant market potential. The Company’s principals have over 40 years of experience in the clinical development of psychotropic drugs and have conducted pivotal studies of many drugs approved by the FDA in psychiatry. They have conducted studies in depression, anxiety, schizophrenia, bipolar disorder, social phobia and sleep disorders. They also have over 40 years of experience in in-patient and out-patient psychiatry, have intimate knowledge of the treatment of Central Nervous System (“CNS”) disorders and have analyzed many potential psychotropic compounds from the standpoint of receptor activity, efficacy, tolerability, side effect/benefit ratio, formulation, ease of administration, cost, and ease of manufacturing.
The Company is in an excellent position to identify and acquire promising psychotropic drugs that, for a variety of reasons, are available from major pharmaceutical companies and other industry and academic sources. The compounds discussed in our Products section represent FKP’s present pipeline.
In contrast to most pharmaceutical or biotechnology companies, FKP has lower overhead costs. Drugs are developed on FKP’s more efficient outsourced structure and accelerated timelines. FKP can economically and efficiently further develop these products, and then out-license them for the completion of development, registration, and commercialization. FKP has developed this pipeline of pharmaceutical products at costs far below those of major pharmaceutical companies; and expects to be an attractive acquisition candidate to companies seeking a major presence in the CNS therapy area. Additionally, as a multi-product company with an attractive pipeline of product opportunities, the Company will consider out-licensing individual compounds or groups of compounds, as well as raising additional capital from institutional investors to further develop the compounds.
FKP has been funded to date largely by the capital of its founders. A small group of private individuals own approximately 11% of the Company. There are no institutional or venture capital shareholders. Milestone payments and products sales under licensing agreements have provided additional funding.